Palabras clave
Asma difícil de tratar
Comorbilidades en asma grave
Cómo citar
Plaudit
Resumen
El asma difícil de tratar es la que no se controla a pesar de las dosis altas o medias de esteroides inhalados o la que requiere altas porciones para mantener un control adecuado de los síntomas y reducir el riesgo de exacerbaciones. Se deben tener en cuenta las fallas en la técnica del uso del inhalador, la pobre adherencia al tratamiento, el tabaquismo, las comorbilidades o el diagnóstico incorrecto. En el asma grave, a pesar de la adherencia al tratamiento con dosis optimizadas y el manejo de los factores contribuyentes, se requieren múltiples medicamentos en dosis máximas para tener un adecuado control, si no es así este no se logra. La dirección de estos pacientes implica un proceso minucioso, dados los múltiples factores que pueden influir en el mal control del asma y que pueden llevar a una inadecuada clasificación de la enfermedad, cuando en realidad puedan estar cursando con diferentes comorbilidades cuyo tratamiento puede disminuir la severidad de los síntomas del asma y modificar el pronóstico. El objetivo de esta investigación es dar a conocer el manejo de los pacientes con asma difícil de tratar y asma grave, así como las comorbilidades más frecuentes. Se realizó una búsqueda en Pubmed con el propósito de identificar las principales patologías que puedan estar presentes y, con base en la literatura, proponer un abordaje diagnóstico. Se incluyeron 100 estudios, incluidas las guías clínicas GINA, GEMA y ERS/ATS.
Referencias
Global Initiative for Asthma. Global strategy for asthma management and prevention (2016 update). 2016. Disponible en: https://ginasthma.org/wp-content/uploads/2016/04/GINA-2016-main-report_tracked.pdf
Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004;125(3):1081-102. DOI: 10.1378/chest.125.3.1081
Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. DOI: 10.1016/j.jaci.2014.08.042
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. DOI: 10.1183/09031936.00202013
Hassan M, Davies SE, Trethewey SP, Mansur AH. Prevalence and predictors of adherence to controller therapy in adult patients with severe/difficult-to-treat asthma: a systematic review and meta-analysis. J Asthma. 2020;57(12):1379-88. DOI: 10.1080/02770903.2019.1645169
Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;4(4):CD012226. DOI: 10.1002/14651858
Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751-3. DOI: 10.1136/thoraxjnl-2011-201096
Global Initiative for Asthma. Global strategy for asthma management and prevention (2021 update). 2021. Disponible en: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf
Plaza V, Alobid I, Alvarez C, Blanco M, Ferreira J, García G, et al. Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies. Arch Bronconeumol (Engl Ed). 2021:S0300-2896(21)00165-4. DOI: 10.1016/j.arbres.2021.05.010
Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. DOI: 10.1183/13993003.00588-2019
Larenas-Linnemann D, Salas-Hernández J, Del Río-Navarro BE, Luna-Pech JA, Navarrete-Rodríguez EM, et al. MIA 2021, Manejo Integral del Asma. Lineamientos para México [MIA 2021, Comprehensive Asthma Management. Guidelines for Mexico]. Rev Alerg Mex. 2021;68(Suppl 1):s1-s122. DOI: 10.29262/ram.v68i5.880
Massoth L, Anderson C, McKinney KA. Asthma and chronic rhinosinusitis: diagnosis and medical management. Med Sci (Basel). 2019;7(4):53. DOI: 10.3390/medsci7040053
Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015;64(2):121-30. DOI: 10.1016/j.alit.2014.12.006
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600
Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22-209. DOI: 10.1002/alr.21695
Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812-20.e3. DOI: 10.1016/j.jaip.2019.05.009
Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al., Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN- and IL-4. J Allergy Clin Immunol. 2012;130(5):1087-96.e10. DOI: 10.1016/j.jaci.2012.05.052
Pothoven KL, Norton J, Ocampo C, Grammer LC, Kern LC, Schleimer RP. Oncostatin M is elevated in chronic rhinosinusitis and decreases barrier function in human airway epithelium. J. Allergy Clin Immunol. 2014;133(2):AB237. DOI: 10.1016/j.jaci.2013.12.841
Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-70.e3. DOI: 10.1016/j.jaip.2016.12.027
Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133-41. DOI: 10.1016/j.jaip.2020.09.063
Castillo JA, Plaza V, Rodrigo G, Julia B, Mullol J. Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study). Eur Respir J. 2013;42(Suppl 57):P3448. Disponible en: https://erj.ersjournals.com/content/42/Suppl_57/P3448
Kalish L, Snidvongs K, Sivasubramaniam R, Cope D, Harvey RJ. Topical steroids for nasal polyps. Cochrane Database Syst Rev. 2012;12:CD006549. DOI: 10.1002/14651858.CD006549.pub2
Zhang Y, Wang C, Huang Y, Lou H, Zhang L. Efficacy of short-term systemic corticosteroid therapy in chronic rhinosinusitis with nasal polyps: a meta-analysis of randomized controlled trials and systematic review. Am J Rhinol Allergy. 2019;33(5): 567-76. DOI: 10.1177/1945892419851312
Rimmer J, Fokkens W, Chong LY, Hopkins C. Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps. Cochrane Database Syst Rev. 2014;(12):CD006991. DOI: 10.1002/14651858.CD006991.pub2
Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol. 2017;140(4):1024-31.e14. DOI: 10.1016/j.jaci.2017.05.044
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209): 1638-50. DOI: 10.1016/S0140-6736(19)31881-1
Stevens WW, Schleimer RP. Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis. Immunol Allergy Clin North Am. 2016;36(4):669-80. DOI: 10.1016/j.iac.2016.06.004
Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin 2013;33(2):163-76. DOI: 10.1016/j.iac.2012.11.002
Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res. 2017;9(4):299-306. DOI: 10.4168/aair.2017.9.4.299.
Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in aspirin exacerbated respiratory disease J Allergy Clin Immun. 2016;137(5):1566-76. DOI: 10.1016/j.jaci.2015.10.020
Liu T, Kanaoka Y, Barrett NA, Feng C, Garofalo D, Lai J, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol 2015;195(8):3537-45. DOI 10.4049/jimmunol.1500905
Avdeeva K, Fokkens W. Precision medicine in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthm R. 2018;18(4):25. DOI: 10.1007/s11882-018-0776-8
Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax. 1952;7(3):213-39. DOI: 10.1136/thx.7.3.213
Paganin F, Trussard V, Seneterre E, Chanez P, Giron J, Godard P, et al. Chest radiography and high resolution computed tomography of the lungs in asthma. Am Rev Respir Dis. 1992;146(4)1084-7.14. DOI:10.1164/ajrccm/146.4.1084
Crimi C, Ferri S, Campisi R, Crimi N. The link between asthma and bronchiectasis: state of the art. respiration. 2020;99(6):463-76. DOI: 10.1159/000507228
Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison?. Curr Opin Allergy Clin Immunol. 2019;19(1):46-52. DOI: 10.1097/ACI.0000000000000492
Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax. 2007;62(3):211-8. DOI: 10.1136/thx.2006.061358
Montull-Veiga B, Amara-Elori I, Menéndez-Villanueva R. Inflamación bronquial y sistémica en las bronquiectasias. En: Martínez García MA (coordiador). Monografía 2: Bronquiectasias [Serie: Crónicas Respiratorias SEPAR]. Barcelona: Ergon Creación; 2016. p. 11-24. Disponible en: https://issuu.com/separ/docs/monografia_2_bronquiectasias
Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways . PLoS One. 2010;5(1):e8578. DOI: 10.1371/journal.pone.0008578
Huang YJ, Nelson CE, Brodie EL, Desantis TZ, Baek MS, Liu J, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol. 2011;127(2):372-81.e1-3. DOI: 10.1016/j.jaci.2010.10.048
Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880-90. DOI: 10.1016/S0140-6736(18)31767-7
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-85. DOI: 10.1164/rccm.201309-1575OC
Zhang SQ, Xiong XF, Wu ZH, Huang TT, Cheng DY. Clinical features of asthma with comorbid bronchiectasis: systematic review and meta-analysis. Medicine (Baltimore). 2021;100(4):e23858. DOI: 10.1097/MD.0000000000023858.
Padilla-Galo A, Olveira C, Fernández de Rota-Garcia L, Marco-Galve I, Plata AJ, Alvarez A, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res. 2018;19(1):43. DOI: 10.1186/s12931-018-0746-7.
Sánchez-Cuellar S, Girón RM, Cisneros C, Caballero P, Tejerina A, Ancochea J. Valoración de bronquiectasias en pacientes con asma. Rev Patol Respir. 2015;18(2):57-62. Disponible en https://www.revistadepatologiarespiratoria.org/descargas/pr_18-2_57-62.pdf
O’Donnell AE. Medical management of bronchiectasis. J Thorac Dis. 2018;10(Suppl 28):S3428-S3435. DOI: 10.21037/jtd.2018.09.39
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3): 1700629. DOI: 10.1183/13993003.00629-2017
Carpagnano GE, Scioscia G, Lacedonia D, Curradi G, Foschino Barbaro MP. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy. 2019;12:83-90. DOI: 10.2147/JAA.S196200
Agarwal R, Sehgal IS, Dhooria S, Aggarwal AN. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med. 2016;10(12):1317-34. DOI: 10.1080/17476348.2016.1249853
Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I, et al. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418-29. DOI: 10.1016/j.jaip.2019.02.030
Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51(4):361-70. DOI: 10.3109/13693786.2012.738312
Sunman B, Ademhan Tural D, Ozsezen B, Emiralioglu N, Yalcin E, Özçelik U. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Front Pediatr. 2020;8:582964. DOI: 10.3389/fped.2020.582964
McCarthy DS, Pepys J. Allergic broncho-pulmonary aspergillosis. Clinical immunology. 2. Skin, nasal and bronchial tests. Clin Allergy. 1971;1(4):415-32. DOI: 10.1111/j.1365-2222.1971.tb00793.x
Denning DW. Diagnosing pulmonary aspergillosis is much easier than it used to be: a new diagnostic landscape. Int J Tuberc Lung Dis. 2021;25(7):525-36. DOI: 10.5588/ijtld.21.0053
Che-Morales JL, Valle-Piña J, Carrillo-Chan J. Síndrome de sobreposición asma-enfermedad pulmonar obstructiva crónica: perfil clínico-funcional [Asthma-chronic obstructive pulmonary disease overlap syndrome: clinical-functional profile]. Rev Med Inst Mex Seguro Soc. 2019;57(5):284-90. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=94871
Postma DS, Rabe KF. The Asthma-COPD Overlap Syndrome. N Engl J Med. 2015;373(13):1241-9. DOI: 10.1056/NEJMra1411863
Plaza V, Álvarez F, Calle M, Casanova C, Cosío BG, López-Viña A, et al. onsensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). Arch Bronconeumol. 2017;53(8):443-49. DOI: 10.1016/j.arbres.2017.04.002
Lainez S, Court-Fortune I, Vercherin P, Falchero L, Didi T, Beynel P, et al. Clinical ACO phenotypes: description of a heterogeneous entity. Respir Med Case Rep. 2019;28:100929. DOI: 10.1016/j.rmcr.2019.100929.
Hikichi M, Hashimoto S, Gon Y. Asthma and COPD overlap pathophysiology of ACO. Allergol Int. 2018;67(2):179-86. DOI: 10.1016/j.alit.2018.01.001
Venkata AN. Asthma-COPD overlap: review of diagnosis and management. Curr Opin Pulm Med. 2020;26(2):155-61. DOI: 10.1097/MCP.0000000000000649
Takayama Y, Ohnishi H, Ogasawara F, Oyama K, Kubota T, Yokoyama A. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis. 2018;13:2525-32. DOI: 10.2147/COPD.S167600
Singh A, Liu C, Putman B, Zeig-Owens R, Hall CB, Schwartz T, et al. Predictors of asthma/COPD overlap in FDNY firefighters with World Trade Center dust exposure: a longitudinal study. Chest. 2018;154(6):1301-10. DOI: 10.1016/j.chest.2018.07.002
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Resp Med 2017;5(12):956-67. DOI: 10.1016/S2213-2600(17)30432-0
Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-61. DOI: 10.1183/09031936.01.00092101
Shirai T, Hirai K, Gon Y, Maruoka S, Mizumura K, Hikichi M, et al. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol Pract. 2019;7(1):134-45.e1. DOI: 10.1016/j.jaip.2018.06.015
Oh JY, Lee YS, Min KH, Hur GY, Lee SY, Kang KH, et al. Increased urinary l-histidine in patients with asthma-COPD overlap: a pilot study. Int J Chron Obstruct Pulmon Dis. 2018;13:1809-18. DOI: 10.2147/COPD.S163189
Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141(4):1169-79. DOI: 10.1016/j.jaci.2018.02.004
Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Resp Med. 2016;4(7):574-84. DOI: 10.1016/S2213-2600(16)30048-0
Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedón JC, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immun. 2011;127(3):741-9. DOI: 10.1016/j.jaci.2010.12.010
McGarry ME, Castellanos E, Thakur N, Oh SS, Eng C, Davis A, et al. Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. Chest. 2015;147(6):1591-8. DOI: 10.1378/chest.14-2689
Lu KD, Breysse PN, Diette GB, Curtin-Brosnan J, Aloe C, Williams DL, et al. Being overweight increases susceptibility to indoor pollutants among urban children with asthma. J Allergy Clin Immun. 2013;131(4):1017-23, 1023.e1-3. DOI: 10.1016/j.jaci.2012.12.1570
Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immun. 2014;133(6):1549-56. DOI: 10.1016/j.jaci.2013.10.006
Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178(7):682-7. DOI: 10.1164/rccm.200801-076OC
Holguin F, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Erzurum SC, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immun. 2011;127(6):1486-93.e2. DOI: 10.1016/j.jaci.2011.03.036
Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J. 2011;38(3):594-602. DOI: 10.1183/09031936.00139810
Scott HA, Gibson PG, Garg ML, Pretto JJ, Morgan PJ, Callister R, et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy. 2013;43(1):36-49. DOI: 10.1111/cea.12004
Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond). 2012;36(3):387-96. DOI: 10.1038/ijo.2011.119
Marsland BJ, Gollwitzer ES. Host-microorganism interactions in lung diseases. Nat Rev Immunol. 2014;14(12):827-35. DOI: 10.1038/nri3769
Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ, et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat Commun. 2015;6:7320. DOI: 10.1038/ncomms8320
Bush A. Pathophysiological mechanisms of asthma. Front Pediatr. 2019;7:68. DOI: 10.3389/fped.2019.00068
Shilovskiy IP, Nikolskii AA, Kurbacheva OM, Khaitov MR. Modern view of neutrophilic asthma molecular mechanisms and therapy. Biochemistry (Mosc). 2020;85(8):854-68. DOI: 10.1134/S0006297920080027
Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014;2(6):645-8; quiz 649. DOI: 10.1016/j.jaip.2014.09.004
Hamilton D, Lehman H. Asthma phenotypes as a guide for current and future biologic therapies. Clin Rev Allergy Immunol. 2020;59(2):160-74. DOI: 10.1007/s12016-019-08760-x
Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219-33. DOI: 10.1007/s12016-018-8712-1
Del Giacco SR, Firinu D, Bjermer L, Carlsen KH. Exercise and asthma: an overview. Eur Clin Respir J. 2015;2:27984. DOI: 10.3402/ecrj.v2.27984
Jayasinghe H, Kopsaftis Z, Carson K. Asthma Bronchiale and Exercise-Induced Bronchoconstriction. Respiration. 2015;89(6):505-12. DOI: 10.1159/000433559
Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015;1(1):15025. DOI: 10.1038/nrdp.2015.25
Chiu CJ, Huang MT. Asthma in the Precision Medicine Era: biologics and probiotics. Int J Mol Sci. 2021;22(9):4528. DOI: 10.3390/ijms22094528
Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG, et al. Roles of Periostin in Respiratory Disorders. Am J Respir Crit Care Med. 2016;193(9):949-56. DOI: 10.1164/rccm.201510-2032PP
Ricciardolo FL, Sorbello V, Ciprandi G. A pathophysiological approach for FeNO: a biomarker for asthma. Allergol Immunopathol (Madr). 2015;43(6):609-16. DOI: 10.1016/j.aller.2014.11.004
Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Resp Crit Care Med. 2013;187(8):804-11. DOI: 10.1164/rccm.201208-1414OC
Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110-19. DOI: 10.1136/thoraxjnl-2018-211540
Agache I. Non-eosinophilic asthma endotypes. Curr Treat Options Allergy. 2015; 2(3): 257-67. DOI: 10.1007/s40521-015-0052-2
Crisford H, Sapey E, Rogers GB, Taylor S, Nagakumar P, Lokwani R, et al Neutrophils in asthma: the good, the bad and the bacteria. Thorax. 2021;76(8):835-44. DOI: 10.1136/thoraxjnl-2020-215986
Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267-81. DOI: 10.2147/JAA.S153097
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2022 Revista Alergia México